La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
CytomX Therapeutics Gestion
Gestion contrôle des critères 3/4
Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.
Informations clés
Sean McCarthy
Directeur général
US$2.6m
Rémunération totale
| Pourcentage du salaire du PDG | 25.0% |
| Durée du mandat du directeur général | 13yrs |
| Propriété du PDG | 0.7% |
| Durée moyenne d'occupation des postes de direction | 3.3yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 4.6yrs |
Mises à jour récentes de la gestion
Recent updates
CytomX Therapeutics' Probody Platform: Potential And Pitfalls In Oncology Treatments
Jul 15The Market Doesn't Like What It Sees From CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Yet As Shares Tumble 30%
Jun 15
We Think Shareholders Are Less Likely To Approve A Pay Rise For CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO For Now
May 09CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling
May 02CytomX Therapeutics, Inc. (NASDAQ:CTMX) Not Doing Enough For Some Investors As Its Shares Slump 27%
Apr 27CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town
Apr 25CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 85%
Mar 05CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Jan 19There's No Escaping CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Muted Revenues Despite A 27% Share Price Rise
Nov 26We're Hopeful That CytomX Therapeutics (NASDAQ:CTMX) Will Use Its Cash Wisely
Nov 17Newsflash: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Analysts Have Been Trimming Their Revenue Forecasts
Mar 29Can CytomX Therapeutics (NASDAQ:CTMX) Afford To Invest In Growth?
Feb 13Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14%
Nov 10CytomX Therapeutics to cut workforce by about 40%
Jul 13CytomX says phase 2 study of breast cancer antibody treatment met main goal
Jul 06Here's Why We're Watching CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation
Jun 08Is CytomX Therapeutics (NASDAQ:CTMX) In A Good Position To Invest In Growth?
Feb 10CytomX: Pullbacks Are Opportunities
Dec 14CytomX: Solving A Critical Problem In The High-Value ADC Space
Sep 15We're Keeping An Eye On CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Rate
Aug 11Checking In On CytomX Therapeutics
Jun 13Shareholders Will Probably Hold Off On Increasing CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO Compensation For The Time Being
Jun 10Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$11m |
| Mar 31 2024 | n/a | n/a | US$17m |
| Dec 31 2023 | US$3m | US$652k | -US$569k |
| Sep 30 2023 | n/a | n/a | -US$10m |
| Jun 30 2023 | n/a | n/a | -US$42m |
| Mar 31 2023 | n/a | n/a | -US$71m |
| Dec 31 2022 | US$3m | US$623k | -US$99m |
| Sep 30 2022 | n/a | n/a | -US$149m |
| Jun 30 2022 | n/a | n/a | -US$143m |
| Mar 31 2022 | n/a | n/a | -US$132m |
| Dec 31 2021 | US$4m | US$616k | -US$116m |
| Sep 30 2021 | n/a | n/a | -US$72m |
| Jun 30 2021 | n/a | n/a | -US$64m |
| Mar 31 2021 | n/a | n/a | -US$61m |
| Dec 31 2020 | US$3m | US$595k | -US$65m |
| Sep 30 2020 | n/a | n/a | -US$54m |
| Jun 30 2020 | n/a | n/a | -US$63m |
| Mar 31 2020 | n/a | n/a | -US$76m |
| Dec 31 2019 | US$4m | US$575k | -US$133m |
| Sep 30 2019 | n/a | n/a | -US$99m |
| Jun 30 2019 | n/a | n/a | -US$99m |
| Mar 31 2019 | n/a | n/a | -US$83m |
| Dec 31 2018 | US$5m | US$550k | -US$85m |
| Sep 30 2018 | n/a | n/a | -US$52m |
| Jun 30 2018 | n/a | n/a | -US$39m |
| Mar 31 2018 | n/a | n/a | -US$50m |
| Dec 31 2017 | US$3m | US$500k | -US$43m |
Rémunération vs marché: La rémunération totale de Sean ($USD 2.61M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 681.57K ).
Rémunération et revenus: La rémunération de Sean a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Sean McCarthy (57 yo)
13yrs
Titularisation
US$2,611,138
Compensation
Dr. Sean A. McCarthy, D.Phil., serves as Independent Director at OncoResponse, Inc. since August 2021. He has been the Chief Executive Officer of CytomX Therapeutics, Inc. since August 2011 and has been it...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Chairman & CEO | 13yrs | US$2.61m | 0.68% $ 651.8k | |
| Senior VP & Chief Scientific Officer | 1.6yrs | US$1.21m | 0.076% $ 73.1k | |
| Senior VP | 3.3yrs | US$1.05m | 0.068% $ 65.1k | |
| Chief Financial Officer | 1.9yrs | pas de données | 0.032% $ 31.2k | |
| Senior VP | 6.3yrs | US$1.21m | 0.083% $ 79.7k | |
| Senior VP & Chief Human Resources Officer | no data | pas de données | pas de données | |
| Senior Vice President of Intellectual Property | 5.5yrs | pas de données | pas de données | |
| Chief Medical Officer | 1.1yrs | pas de données | pas de données | |
| Senior Vice President of Quality & Product Manufacturing | 1.6yrs | pas de données | pas de données | |
| Special Advisor to Chief Executive Officer | no data | US$273.54k | pas de données |
3.3yrs
Durée moyenne de l'emploi
55.5yo
Âge moyen
Gestion expérimentée: L'équipe de direction de CTMX est considérée comme expérimentée (ancienneté moyenne 3.3 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Chairman & CEO | 13yrs | US$2.61m | 0.68% $ 651.8k | |
| Independent Director | 5.3yrs | US$75.12k | 0.0066% $ 6.3k | |
| Member of Scientific Advisory Board | 4.6yrs | pas de données | pas de données | |
| Member of Scientific Advisory Board | no data | pas de données | pas de données | |
| Independent Director | 3.7yrs | US$78.62k | 0% $ 0 | |
| Independent Director | 5.7yrs | US$77.12k | 0% $ 0 | |
| Lead Independent Director | 8.9yrs | US$105.12k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$80.62k | 0% $ 0 | |
| Member of Scientific Advisory Board | 3.7yrs | US$8.03m | pas de données | |
| Independent Director | 2.9yrs | US$69.12k | 0% $ 0 | |
| Member of Scientific Advisory Board | 4.6yrs | pas de données | pas de données | |
| Member of Scientific Advisory Board | 1.6yrs | pas de données | pas de données |
4.6yrs
Durée moyenne de l'emploi
61yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de CTMX sont considérés comme expérimentés (ancienneté moyenne 4.6 ans).